by The North America life science tools market size was valued at USD 44.5 billion in 2023 and is projected to surpass around USD 133.95 billion by 2033 and is expected to grow at a compound annual growth rate (CAGR) of 11.65% from 2024 to 2033.
Increased government funding for life science technologies is anticipated to significantly propel the market. Organizations like The National Human Genome Research Institute (NHGRI) and the National Institutes of Health (NIH) are actively funding multiple life science projects. NHGRI collaborates with researchers and scientists to provide funds for genomic research, focusing on identifying the genomic basis of human diseases and health, and understanding the complexities associated with the human genome. NHGRI is dedicated to applying genomic technologies to enhance patient care and benefit society.
NIH’s Glycoscience Program, 4D Nucleome Program, and Gabriella Miller Kids First Pediatric Research Program are common fund awards supporting biomedical research. During the Covid-19 pandemic, the U.S. FDA granted Emergency Use Authorizations (EUAs) to various diagnostic tests, making them rapidly and easily available. EUAs were issued for different types of Covid-19 tests, including PCR-based molecular tests and serological & antigen tests. Thermo Fisher, in March 2020, announced the development of up to 5 million Covid-19 test kits.
In May 2020, the company reported the FDA’s expanded EUA for the TaqPath Covid-19 Combo Kit, developed by Thermo Fisher along with Applied Biosystems’ 7500 Real-time PCR series system. In June 2020, Biocept, Inc. announced the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR-based testing for Covid-19.
Apart from PCR, several other nucleic acid assays, including isothermal amplification assays, amplicon-based metagenomics sequencing, hybridization microarray assays, and CRISPR-related technologies, are gaining momentum in the marketplace. The number of FDA EUA-approved tests is continually increasing, with numerous tests under development.
Key Pointers
- In 2023, the United States held a dominant 88% revenue share in the North American market.
- In terms of End Use, the healthcare sector’s revenue share in 2023 was approximately 37%.
- In terms of revenue share by technology, the cell biology category in 2023 accounted for about 36%.
- In terms of revenue share by product, the cell biology section has achieved approximately 25% by 2023.
Get a Sample: https://www.visionresearchreports.com/report/sample/41152
Technology Insights
In 2023, cell biology technology dominated the market, accounting for the largest revenue share of over 36%. The steady growth of this segment can be attributed to the relevance of cell biology technology in drug discovery and the increased funding from NIH/NSF for cell biology.
Advancements in liquid handling and flow cytometry have significantly expanded the applications of cell-based assays in drug discovery. Additionally, the late-stage failure of pre-clinical animal models during drug discovery has driven the adoption of cell-based assays, offering a practical alternative by predicting in vivo activities of novel drug candidates. Mass spectrometry plays a crucial role in proteomic workflows.
Technological advancements in mass spectrometry contribute to enhanced proteomic discovery capabilities. The development of high-mass accuracy, high-resolution mass spectrometers, such as Orbitrap and time-of-flight (TOF) mass analyzers, has improved the identification of posttranslational modifications and peptides. The enhancement of mass resolution has widened the overall mass range, leading to more efficient analysis.
Product Insights
The cell biology product segment emerged as the leader in the global market in 2023, capturing a revenue share of over 25%. Researchers in the life science industry are increasingly adopting modern instruments, driving growth in this segment. This trend has prompted several manufacturers, including Cytiva, Horizon Discovery, BioTek Instruments, and Seahorse Bioscience, to expand their portfolios by developing instruments specifically related to cell biology, analysis, and imaging.
Different cell biology applications necessitate specific sets of protocols, techniques, and laboratory instruments. Early developments in this segment have provided scientists with valuable insights, leading to the mainstream adoption of instruments like confocal scanning microscopy and electron microscopy. Recent trends in the life science tools industry have spurred technological interventions aimed at advancing drug research.
The integration of smart technology has improved the efficiency of patient assessment, resulting in increased demand for separation technologies, Next-Generation Sequencing (NGS), and PCR. Additionally, the development of integrated devices such as MRI scans, in-patient monitoring and management tools, and laboratory equipment is contributing to enhanced patient assessment and management, thereby propelling the market.
These integrated devices enable healthcare professionals to process the necessary data for prescribing the right medications to patients. Collaborations among various industry stakeholders have significantly driven innovations in this field, encouraging emerging entities to invest in the development of modern life science tools. Furthermore, the introduction of modern tools such as bi-specific antibodies, nanosensors, and computational biology has fostered collaborations across different disciplines, including flow cytometry, mass spectrometry, and nucleic acid microarray.
End-use Insights
In 2023, the healthcare sector dominated the end-use segment, commanding a revenue share of over 37%. Numerous hospitals and clinics are actively providing sequencing services to patients, incorporating this technology into routine medical practices. For instance, Stanford Medicine offers sequencing services to individuals with rare or undiagnosed genetic conditions. Partners HealthCare in the U.S. stands out as one of the first hospital systems providing genomic sequencing, analysis, and interpretation services to the public. They have enrolled over 200 patients and physicians in an NIH-funded study to investigate the integration of whole-genome sequencing in clinical medicine.
The industrial sector encompasses the applied applications of life science tools in fields such as bioengineering and applied biosciences. This sector is characterized by multidisciplinary research in biological engineering and novel biosciences domains, including biochemical engineering and pharmaceutical engineering. Proteomics technology plays a crucial role in drug discovery, development, neuroscience, apoptosis, and toxicology analysis. The knowledge derived from proteomics science has also been applied in the food industry to characterize and map changes in the protein components present in foods during production.
Regional Insights
In 2023, the U.S. dominated the North American market, securing a revenue share exceeding 88%. The anticipated growth of the U.S. market is driven by the application of life sciences tools in disease diagnosis. For example, in June 2020, the FDA granted emergency use authorization for the COVIDSeq Test, an NGS-based Covid-19 diagnostic test developed by Illumina. The use of NGS enables the extraction of viral genomic sequences from samples, facilitating research to understand mutation patterns of the virus.
The U.S. hosts numerous conferences and seminars related to life science research, keeping researchers updated with the latest technologies and consequently driving the adoption of life science tools. An example is the 69th ASMS Conference on Mass Spectrometry and Allied Topics organized by the American Society for Mass Spectrometry in June 2021 in Philadelphia. Such initiatives are expected to contribute to increased revenue generation in the U.S. life science tools market.
In Canada, increased funding by the government has spurred R&D in biotechnology, leading to heightened demand for life science tools and boosting market growth. In October 2020, the Canadian government announced a USD 6.5 million investment for Toronto Innovation Acceleration Partners (TIAP), a membership-based organization comprising research hospitals, institutions, and top universities in Canada working to improve and advance various health science technologies.
Read More: https://www.heathcareinsights.com/ai-in-life-science-analytics-market/
North America Life Science Tools Market Key Companies
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Agilent Technologies
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- General Electric Company
- Merck KGaA
- QIAGEN
- Corning, Inc.
- Perkin Elmer, Inc.
- Miltenyi Biotec
- Bruker
- Hitachi Koki Co., Ltd.
- Shimadzu Corporation
- Oxford Instruments
North America Life Science Tools Market Segmentations:
By Technology
- Genomic Technology
- Proteomics Technology
- Cell Biology Technology
- Other Analytical & Sample Preparation Technology
- Lab Supplies & Technologies
By Product
- Next-Generation Sequencing
- PCR & qPCR
- Flow Cytometry
- Nuclear Magnetic Resonance Spectroscopy (nmr)
- Microscopy & Electron Microscopy
- Liquid Chromatography (lc)
- Mass Spectrometry (MS)
- Nucleic Acid Preparation (NAP)
- Transfection Electroporation
- Cell Biology
- Cloning
- Other Products & Services
By End-use
- Government & Academic
- Biopharmaceutical Company
- Healthcare
- Industrial Application
- Others
By Country
- U.S.
- Canada
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41152
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
